GREAT NECK, N.Y.--(BUSINESS WIRE)--Neogenix Oncology, Inc. (Neogenix) announced today that the Institutional Review Board (IRB) at Conemaugh Valley Memorial Hospital (Memorial Medical Center) in Johnstown, Pennsylvania, has approved the company’s protocol for its first Diagnostic Clinical Trial. The study is designed to assess the effectiveness of a panel of Neogenix monoclonal antibodies as diagnostic markers for colorectal and pancreatic cancer. Previous developmental efforts have focused on the role of the lead candidate monoclonal, NPC-1C as a therapeutic agent for these malignancies.
